Brand

Five things for pharma marketers to know: Friday, July 15, 2016

Five things for pharma marketers to know: Friday, July 15, 2016

By

PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit

Can pharma movement campaigns flourish on both sides of the Atlantic?

Can pharma movement campaigns flourish on both sides of the Atlantic?

By

Executives attending Cannes Lions Health weigh in on the imbalance seen in the U.S. between branded and unbranded drug ads.

Cannes: The Heat Is On

Cannes: The Heat Is On

By

A rundown of MM&M at Cannes, and five burning questions heading into the Lions Health festival and awards.

Balancing Opportunity and Responsibility in Healthcare Targeting

Balancing Opportunity and Responsibility in Healthcare Targeting

If you truly understand who your high writers and compliant patients are, you'll understand when and how to communicate with prospects that look and act like them.

What Brand Won the Super Bowl of Pharma?

What Brand Won the Super Bowl of Pharma?

Pharma marketers are wondering if these exorbitant media buys ($4.9 million for 30 seconds) were worth the investment for Valeant and AstraZeneca. Was either strategy successful?

Urhekar, in biggest move yet as Americas president, unites McCann Health NA agencies

Urhekar, in biggest move yet as Americas president, unites McCann Health NA agencies

By

IPG's McCann Health announces branding and operational changes aimed at integrating its US and Canadian shops.

Five things for pharma marketers to know: November 11, 2015

Five things for pharma marketers to know: November 11, 2015

By

Dr. Reddy's is blocked from selling generic purple Nexium; the FDA approves Roche's melanoma drug; Novartis says Entresto keeps heart-failure patients from being readmitted to the hospital

An Open Letter: Allowing Regional Flexibility Bolsters Global Branding

An Open Letter: Allowing Regional Flexibility Bolsters Global Branding

We're not out to reinvent the wheel if we don't have to but we will need to localize the campaign for New Zealand and do what is right for our physicians and our patients.

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Is It Finally Time for Pharma to Change the Way It Uses Facebook?

Pharma has hidden behind the ability to turn commenting off on Facebook pages, allowing marketers to use the channel much as they would a typical web page.

Mullen Lowe's Sokoloff closes Lions Health

By

The second annual Lions Health creativity festival ended Saturday.

A Q&A with Sir Roger Moore, 2015 Young Lions Health Award judge

A Q&A with Sir Roger Moore, 2015 Young Lions Health Award judge

By

Moore, a longtime Goodwill Ambassador for Unicef, talked with MM&M about how creativity can be used to improve public health.

Is Digital Marketing a Dead-End Job?

Is Digital Marketing a Dead-End Job?

Either we need to stop calling it digital marketing (because digital is baked into business) and just consider it marketing. If we feel like we can't, then digital might very well be a dead-end job.

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

The New Holistic Approach to Leveraging a Multi-Channel Contact Center

Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.

Merck's Heller on how to get more women into the C-suite

Merck's Heller on how to get more women into the C-suite

By

Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.

Docs cozy up to brands that bring unique benefits, thought-leader backing

Docs cozy up to brands that bring unique benefits, thought-leader backing

By

Physician trust in pharmaceutical brands is driven by an emotional connection as well as functional attributes and perceptions of the manufacturer, said Harris Interactive, which found Advair, Spiriva and Mirena to be tops in their categories with doctors.

Hologic, seeking rights to Makena, trades barbs with KV

By

Hologic alleges KV has botched the marketing and wants rights to the drug. KV disagrees.

Herceptin treatment time scrutinized by researchers

By

A government-funded study looks at whether patients with breast cancer really need 12 months of the treatment.

Copaxone sales likely to top out this year, Teva exec says

By

Sales of Teva's MS blockbuster Copaxone are likely to peak this year before giving way as more therapeutic options become available, a Teva exec says.

Endo rebrands to move beyond roots in pain drugs

Endo rebrands to move beyond roots in pain drugs

By

Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.

FDA gives guidance on brand, generic names in ads

By

The FDA issued guidance clarifying narrow questions of scientific or generic name placement in ads and labeling in different media, including electronic media.

As GSK jettisons consumer brands, smaller marketer sees boon

As GSK jettisons consumer brands, smaller marketer sees boon

By

GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.

As brand revenue shrinks, so does brand promotion

By

Branded drug sales declined 0.7% to $229 billion last year, according to IMS Health, and that's having an impact on promotional spend.

Viagra, Nexium and Chantix are Mensa-worthy brands, says digital IQ study

Viagra, Nexium and Chantix are Mensa-worthy brands, says digital IQ study

By

Marketers working on Pfizer brands Viagra and Chantix, and AstraZeneca's Nexium, can pat themselves on the back, since they all scored in the "genius" percentile based on digital marketing competency, according to the L2 Digital IQ Index.

E-samples hijack search, study asserts

E-samples hijack search, study asserts

By

Many big pharma firms are running e-samples, a form of marketing which researchers say capitalizes on patients seeking health information and may affect prescribers' preference for brands over generics.

UCB turns Crohn's patients into brand advocates

UCB turns Crohn's patients into brand advocates

By

UCB launched a multifaceted campaign for its Cimzia injectable, calling on patients and doctors to publicly educate others about Crohn's disease and treatment.

Last chance to grab glory

Last chance to grab glory

If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.

Abbott, AZ extend co-promotion to Trilipix

Abbott, AZ extend co-promotion to Trilipix

By

AstraZeneca will help Abbott reach more physicians with its Trilipix (fenofibric acid) drug, a cholesterol product approved by FDA last December. The companies also filed an NDA for Certriad, a Trilipix/Crestor combination drug.

Gelnique ads swap embarrassment for empowerment

Gelnique ads swap embarrassment for empowerment

By

Watson launched a campaign today for its overactive bladder product Gelnique - the first topical gel indicated for the disorder - featuring younger, active women.

Worldwide, consumers prefer generics, says study

By

Consumers worldwide overwhelmingly prefer medicines that have been around a long time to the latest treatments, and over half prefer generics to branded drugs given the choice, according to a DDB Health survey.

GSK pairs Wynonna Judd album with Alli

By

Consumers purchasing GSK's weight loss drug Alli will receive a free copy of Wynonna Judd's new album "Sing," beginning in March.

OPINION

Email Newsletters